02 Jun Aegis Sciences Corporation Announces Expanded Testing Menu
NASHVILLE, TN. (June 1, 2025) – Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce an updated testing menu which will include new novel psychoactive substances (NPS) and behavioral health medications.
Aegis’s NPS testing menu is reviewed regularly to update the offering in a manner that allows it to maintain clinical relevance. Aegis regularly updates its NPS testing menu based on recommendations established collaboratively by the Center for Forensic Science Research and Education (CFSRE) and the Society of Forensic Toxicologist (SOFT) NPS Committee. Updates to the testing menu include CFSRE’s tier one and tier two scope recommendations for Quarter 4 of 2024.
This year’s first bi-annual update to its novel psychoactive substance (NPS) testing menu will include etomidate, a sedative hypnotic drug identified in the illicit drug supply, 4Cl-MDMB-BUTINACA, a new synthetic cannabinoid and multiple synthetic stimulants and designer opioids (including newly observed nitazene analogs such as fluetonitazene and n-pyrrolidino fluetonitazene which have been demonstrated to be significantly more potent than fentanyl).
“These updates provide clinicians with critical information to help inform appropriate treatment decisions based on what novel substances are in the current drug supply,” said Dr. Josh Schrecker, Sr. Dir. of Clinical Affairs at Aegis Sciences Corporation.
The expanded behavioral health testing menu will include new prescription medications, lemborexant, viloxazine, benztropine, trihexyphenidyl and lumateperone, giving providers the opportunity to monitor patient compliance more effectively. This update also includes lowered thresholds for select benzodiazepines to enhance providers’ ability to detect and assess the presence of these drugs more accurately. “Aegis’s thresholds remain grounded in evidence-based literature to ensure clinical relevance and analytical accuracy. Our R&D team optimizes detection of these compounds in urine and oral fluid in order to provide the most complete, accurate results.” said Dr. Rebecca Heltsley, Senior Vice President, Research and Development at Aegis Sciences Corporation.
Health care practitioners can learn more about the updated test offering through the Aegis website: www.aegislabs.com
